Ref.: BL-RE-091709Manufacturer ref.: ERFASLGX10 10 x 96 tests
€4,815.00 excl. VAT
CD178 is a type II membrane protein with the N-terminal end in the cytoplasm and the C-terminal region extending into the extracellular space. Its receptor, FasR, is a type I membrane protein of cellular surface...
Accession number
P36940
Dose range
82.30 to 60.000 pg/ml
Sensitivity of the dosage
90 pg/ml
Conjugate
Biotin
Product type
ELISA
Brand
Invitrogen
CD178 is a type II membrane protein with the N-terminal end in the cytoplasm and the C-terminal region extending into the extracellular space. Its receptor, FasR, is a type I membrane protein of cellular surface...
CD178 is a type II membrane protein with the N-terminal end in the cytoplasm and the C-terminal region extending into the extracellular space. Its receptor, FasR, is a type I cell surface membrane protein and a member of the NGF TNFet receptor family. As a member of the TNF-cytokine family, CD178 induces apoptosis during interaction with FasR. CD178 may exist as a bound (45 kD) or soluble (26 kD) membrane. The soluble protein can be released from the cells during cleavage by metalloproteinases. The binding of CD178 to Fas leads to receptor oligomerization and triggers death of apoptotic cells through the interaction of other proteins. CD178 is expressed predominantly in activated T-cells and natural killer cells, and also in tissues of immunological sites such as testicles and eyes. CD178 expression is also reported in a variety of tissues such as thymus, liver, lovary, lung, heart and kidney. It is assumed that CD178 induction of apoptosis is predominantly involved in antiviral immune responses. CD178 is a cell surface molecule belonging to the tumour necrosis factor family, and binds to its Fas receptor, thus inducing l-apoptosis. Different cells express Fas, where CD178 is expressed mainly on activated T cells. FAS and CD178 are involved in the downward regulation of immune reactions as well as T-cell cytotoxicity. CD178 concentration was also shown to be associated with atherosclerosis and inflammatory disease in patients with hypertension
Sensitivity
Sensitivity of the dosage: 90 pg/ml.
Measurement range
Dose range: 82.30 to 60.000 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Coefficient of intradose variation < 10%, interdose < 12%.